文献速递生殖医学妇科

多内分泌代谢性卵巢综合征不孕的体外成熟:治疗方案与结局的系统综述

In vitro maturation for infertility in polyendocrine metabolic ovarian syndrome: a systematic review of treatment protocols and outcomes.
PubMed 文献 · Fertil Steril · 2026-08-12

该系统综述检索多个数据库,汇总多内分泌代谢性卵巢综合征(PMOS)女性采用不同体外成熟(IVM)方案的数据。所有方案基本消除卵巢过度刺激综合征(OHSS),成熟率标准IVM约50%、hCG预处理或双相方案60%-70%,单次取卵后活产率约20%-48%。证据以单中心队列为主,异质性大未能统计合并。

要点

  • 所有IVM方案基本消除PMOS患者的OHSS风险。
  • 双相CAPA-IVM方案成熟率与胚胎产出最高,且有随机试验支持全无激素方案可行。
  • 单次取卵后活产率约20%-48%,受预处理策略、培养系统及移植政策影响。

核心结论

  • IVM是PMOS不孕患者避免OHSS的可行选择,但方案间结局差异大且证据质量有限。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase、Web of Science和Cochrane数据库,汇总PMOS女性使用IVM方案的相关已发表数据。

主要发现

  • 所有IVM方案基本消除OHSS。
  • 标准IVM成熟率约50%,hCG预处理或双相方案成熟率60%-70%。
  • 单次取卵后活产率约20%-48%,随预处理策略、培养系统和胚胎移植政策变化。
  • CAPA-IVM方案与最高成熟率和胚胎产出相关,随机试验报告全无激素CAPA-IVM方案可行。
  • 产科、新生儿、表观遗传及儿童神经发育结局随访至5-7岁令人放心。

关键数值与推荐

  • 标准IVM成熟率约50%。
  • hCG预处理或双相方案成熟率60%-70%。
  • 单次取卵后活产率约20%-48%。

临床怎么用

  • PMOS不孕患者可考虑IVM以规避OHSS,方案选择需权衡成熟率与胚胎产出。
  • CAPA-IVM方案可能提高成熟率和胚胎产出,全无激素方案可行。

局限性

  • 临床和方法学异质性大,无法进行统计合并。
  • 证据以单中心队列为主,随机试验少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In vitro maturation (IVM) involves the retrieval of immature oocytes from unstimulated or minimally primed antral follicles, with maturation completed in culture. Women with polyendocrine metabolic ovarian syndrome (PMOS), the condition previously known as polycystic ovary syndrome, are the prototypical candidates for oocyte IVM because it largely avoids ovarian hyperstimulation syndrome (OHSS). Several IVM protocols are in clinical use, differing in priming (human chorionic gonadotropin [hCG], follicle-stimulating hormone [FSH], or none) and culture system (standard vs. biphasic capacitation [CAPA-IVM]). We systematically reviewed published data relating to the use of the above IVM protocols in women with PMOS that were identified by literature searching (MEDLINE, Embase, Web of Science, Cochrane). All IVM protocols essentially eliminated OHSS. Oocyte maturation, number of usable embryos, and the live birth rate varied by priming strategy, culture system, and embryo transfer policy. Maturation rates were approximately 50% with standard IVM and 60%-70% with the hCG-primed or biphasic protocols, and live birth rate after a single retrieval was approximately 20%-48%. The CAPA-IVM protocol was associated with the highest maturation and embryo yield, and a randomized trial reported that a fully hormone-free CAPA-IVM protocol is feasible. Obstetric, neonatal, epigenetic, and child-neurodevelopmental outcomes, now reported up to age 5-7 years, are reassuring. Clinical and methodological heterogeneity precluded statistical pooling of data, and the evidence remains dominated by single-center cohorts, with few randomized trials. This article summarizes protocol-specific outcomes, identifies determinants of success, and defines priorities for standardizing IVM and generating higher-quality evidence for the use of IVM in PMOS.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Vuong LN, Pham TD, Le HL, et al. In vitro maturation for infertility in polyendocrine metabolic ovarian syndrome: a systematic review of treatment protocols and outcomes. Fertil Steril. 2026. PMID: 42586493. doi:10.1016/j.fertnstert.2026.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。